Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer

Efficacy and safety of biweekly cetuximab plus irinotecan were evaluated to provide guidance for its use in Japan as third‐line treatment for pretreated metastatic colorectal cancer (mCRC) patients harboring wild‐type KRAS exon 2. Objective response rate (ORR) was used as primary endpoint based on a...

Descripción completa

Detalles Bibliográficos
Autores principales: Osumi, Hiroki, Shinozaki, Eiji, Mashima, Tetsuo, Wakatsuki, Takeru, Suenaga, Mitsukuni, Ichimura, Takashi, Ogura, Mariko, Ota, Yumiko, Nakayama, Izuma, Takahari, Daisuke, Chin, Keisho, Miki, Yoshio, Yamaguchi, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113428/
https://www.ncbi.nlm.nih.gov/pubmed/29908105
http://dx.doi.org/10.1111/cas.13698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113428/
https://www.ncbi.nlm.nih.gov/pubmed/29908105
http://dx.doi.org/10.1111/cas.13698

Ejemplares similares